tiprankstipranks
In this article:
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol Myers (BMY) and Eli Lilly & Co (LLY)

In this article:
In this article:

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol Myers (BMYResearch Report) and Eli Lilly & Co (LLYResearch Report).

Bristol Myers (BMY)

Barclays analyst Carter Gould maintained a Hold rating on Bristol Myers on April 29 and set a price target of $68.00. The company’s shares closed last Friday at $75.27, close to its 52-week high of $78.17.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 2.3% and a 46.6% success rate. Gould covers the Healthcare sector, focusing on stocks such as Applied Therapeutics, Molecular Templates, and Gilead Sciences.

Bristol Myers has an analyst consensus of Moderate Buy, with a price target consensus of $74.43.

See Insiders’ Hot Stocks on TipRanks >>

Eli Lilly & Co (LLY)

Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Eli Lilly & Co yesterday and set a price target of $356.00. The company’s shares closed last Friday at $292.13, close to its 52-week high of $314.00.

According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.4% and a 47.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $314.21, representing a 6.2% upside. In a report issued on April 29, Truist Financial also maintained a Buy rating on the stock with a $342.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed